BOSTON, Aug. 26, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced that its Board
of Directors have elected Maykin Ho, Ph.D., to the Board, effective
August 26, 2015.
Dr. Ho is a retired partner of the Goldman Sachs Group where she
served as advisory director of Global Healthcare Investment
Banking, as senior biotechnology analyst, and as co-head of
healthcare for Global Investment Research. Earlier in her
career, Dr. Ho held various managerial positions in licensing,
strategic planning, marketing and research at DuPont-Merck
Pharmaceuticals and DuPont de Nemours & Company.
"With more than 30 years of experience in the healthcare and
finance industries, Dr. Ho is an excellent addition to our Company,
and we welcome her to our Board of Directors," said Josef von Rickenbach, Chairman and Chief
Executive Officer, PAREXEL. "As we continue to be a premier
provider to the biopharmaceutical industry in the development and
commercialization of new and innovative drug treatments worldwide,
our clients and shareholders will benefit from Maykin's expertise,
insight and perspective."
Dr. Ho is a member of the Board of Directors of the Aaron
Diamond AIDS Research Center and of Agios Pharmaceuticals. She
formerly served on the Investment Committee of the Society of
Neuroscience, as well as the Advisory Council for the Department of
Biological Chemistry and Molecular Pharmacology of the Harvard Medical School.
"PAREXEL is a leader in biopharmaceutical drug development, and
I am honored to join the Board of Directors," said Dr. Ho. "I
look forward to working with the Board of Directors and the
management team to help achieve the Company's operational and
financial goals and advance PAREXEL's mission to make the world a
healthier place."
After receiving her Ph.D. in microbiology and immunology and a
B.S. in biology from the State University of
New York, Downstate Medical Center, Dr. Ho was a
postdoctoral fellow at Harvard Medical School. She is also a
graduate of the Advanced Management Program at Duke University's Fuqua
School of Business.
Dr. Ho's accomplishments have been recognized in the industry.
Among her awards and honors, she received the 2007 Asian Women in
Business Corporate Leadership Award and the 2004 National
Association for Asian American Professionals Leadership Award.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL has offices in 80 locations in 51
countries around the world, and had approximately 18,660 employees
in the fourth quarter. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings, including expense
savings from the $30 – $45 million restructuring charge disclosed in the
press release dated June 23, 2015;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the acquisitions of ClinIntel Limited
and Quantum Solutions India, or enter into new lines of business;
the impact on the Company's business of government regulation of
the drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of foreign
currency exchange rate fluctuations and other international
economic, political, and other risks. Such factors and
others are discussed more fully in the section entitled "Risk
Factors" of the Company's Annual Report on Form 10-K for the fiscal
year ended June 30, 2015 as filed
with the Securities and Exchange Commission on August 25, 2015, which "Risk Factors" discussion
is incorporated by reference in this press release. The
Company specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin, PAREXEL
International
Tel: +1 781-434-5516
Email:
Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-names-maykin-ho-to-board-of-directors-300133065.html
SOURCE PAREXEL International Corporation